$7.40 0.14 (+1.93%)
11/6/2009 4:00 PM

Rigel Pharmaceuticals, Inc. (RIGL)

CAPS Rating: 2 out of 5

The Company is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases.

Current Price $7.40 Mkt Cap $383.48M
Open $7.19 P/E Ratio 0.00
Prev. Close $7.26 Div. (Yield) N/A (N/A)
Daily Range $7.17 - $7.56 Volume 551,955
52-Wk Range $4.19 - $14.75 Avg. Daily Vol. 892,000

RIGL News and Commentary

Caps

How do you think RIGL will perform vs the S&P 500?

Add Stock to Watchlist

All Members

108 Outperform
60 Underperform
 

All-Star Members

38 Outperform
28 Underperform
 

Wall Street

7 Outperform
1 Underperform
 

Top RIGL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

AhWu (87.13)
Submitted November 10, 2008

Stock has been unfairly punished over a slightly worrisome side effect in data from their their clinical trials for their oral Rheumatoid arthritis drug -- patients experienced increases in blood pressure, but those increases were manageable. It… More

0 Comments | Reply | Report this Post

ScreenerStizBear (< 20)
Submitted June 26, 2008

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

0 Comments | Reply | Report this Post
RIGL VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about RIGL.

Recs

0
Member Avatar ablengata (48.23) Submitted: 11/3/2009 8:28:35 PM : Outperform Start Price: $7.20 RIGL Score: +1.24

with their new drug r788 moving along, and with the stock price at 50% the value it was over the summer due to a huge (overreaction) selloff resulting from the taski results, this stock is ready for a rebound for the short term. At the same time, it is a very speculative biotech stock, so I won't consider RIGL a complete winner until their arthritis drug is solid; that probably wont be for at least a year. But short term, this stock is ready to rebound a bit.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar Roto1177 (77.77) Submitted: 10/20/2009 9:29:42 PM : Outperform Start Price: $6.89 RIGL Score: +9.15

CAPS ALL STAR

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar 08PortfolioModel (< 20) Submitted: 10/20/2009 12:11:27 AM : Outperform Start Price: $6.69 RIGL Score: +11.22

Current 6.99, Oct 19 09. Limit 5.75

Report this Post 0 Comments | Reply | Permalink
View All 24 Pitches »

Leaderboard

Find the members with the highest scoring picks in RIGL.

Score Leader

fluxxdeluxx

fluxxdeluxx (< 20) Score: +134.81

The Score Leader is the member with the highest score across all their picks in RIGL.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
schwah8 99.66 10/13/2008 Underperform NS $18.26 -59.47% +16.34% +75.81
cybob2000 < 20 10/23/2008 Underperform 3W $15.64 -52.69% +21.73% +74.42
seanchile 98.71 1/18/2008 Underperform 3Y $28.03 -73.60% -17.14% +56.46
darksider389 50.43 7/7/2008 Underperform 3M $21.97 -66.32% -11.22% +55.10
chilejohn 80.29 1/28/2008 Underperform 3M $25.55 -71.04% -16.22% +54.82
duchey 90.82 1/28/2008 Underperform 1Y $25.55 -71.04% -16.22% +54.82
flats66 < 20 8/14/2008 9/18/2009 Underperform 3Y $22.71 -67.42% -13.56% +53.86
ScreenerStizBear < 20 6/26/2008 Underperform NS $22.85 -67.61% -14.32% +53.29 1 Comment
eXigy 98.92 2/4/2008 Underperform NS $26.62 -72.20% -19.46% +52.75
supershark 65.99 1/15/2008 Underperform 3Y $26.32 -71.88% -20.13% +51.75
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackRodmanRen < 20 6/9/2009 Outperform NS $10.07 -26.51% +14.60% -41.11
TrackRBCCapMkts 81.74 1/30/2009 Underperform NS $6.80 +8.82% +28.30% +19.47
TrackOppenheimer 26.63 12/1/2008 Outperform NS $7.22 +2.49% +25.60% -23.11
TrackRBCCapMkts 81.74 9/3/2008 Outperform NS $23.35 -62.87% -31.71% -31.16 10/28/2008 @ $8.67
TrackCitigroup 21.22 8/27/2008 Outperform NS $22.40 -58.21% -23.67% -34.55 7/24/2009 @ $9.36
TrackStanfordRes 80.42 7/22/2008 Outperform NS $24.58 -69.89% -11.67% -58.23
TrackFortisBank 86.13 1/7/2008 Outperform NS $24.19 -69.41% -21.27% -48.14
TrackLehmanBros 76.60 12/14/2007 Outperform NS $27.33 -72.92% -24.13% -48.80
TrackCreditSuiss 91.16 7/19/2007 Outperform NS $8.76 -15.53% -27.34% +11.81
TrackJefferies 75.83 6/8/2007 Outperform NS $9.50 -22.11% -24.24% +2.14

Featured Broker Partners